Stemrim Inc.TSE: 4599

StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis

Jun 16, 2026 at 6:45 AM UTC · Issued by Stemrim Inc. via TDnet

Stemrim Inc. (4599) Press Release

View Attachment

Company analysis

Earlier from Stemrim

Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]Jun 10

All Stemrim news releases